Peptide Law in Maryland
Last reviewed
Status overview
Maryland is a restrictive-tier state for compounded peptide access in 2026. The April 15 federal reclassification provides the legal floor, but state pharmacy board requirements set the actual ceiling on access.
Known friction. Stricter compounding pharmacy oversight regime. May require an in-state pharmacy or face delays. Non-resident pharmacy registration likely required.
What this means in practice
- Prescription path. A valid prescription from a licensed practitioner is required. Telehealth prescribing is generally accepted but verify with your specific compounder.
- Compounding pharmacy access. National compounders may or may not hold Maryland non-resident pharmacy licenses. Always verify before assuming your preferred pharmacy can ship to you.
- Lead time. Expect 14-21 days additional lead time. Strongly consider using an in-state compounder if available.
- Post-PCAC outlook. The July 2026 PCAC decision will not change state-level pharmacy board requirements. Federal compounding approval and state pharmacy regulation are distinct frameworks.
Key contacts
- State Board of Pharmacy: Search for “Maryland Board of Pharmacy” to verify compounder licenses and file complaints if needed.
- State Medical Board: For prescriber verification and telehealth practice rules.
Pharmacy considerations
When selecting a compounding pharmacy to serve Maryland, use the 10-point checklist in Chapter 7 of the Peptide Law Playbook. For restrictive-tier states, prioritize compounders who explicitly advertise holding the required non-resident license(s).
Last verified: April 2026. State pharmacy regulations change, often quietly. Verify current requirements with the compounding pharmacy before ordering.